Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes?

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 366–367 (2006)Cite this article

boxed-textKeech A et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366: 1849–1861

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mazzone T (2005) Reducing cardiovascular disease in patients with diabetes mellitus. Curr Opin Cardiol 20: 245–249

    Article  Google Scholar 

  2. Mazzone T (2004) Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 93 (Suppl 1): 27C–31C

    Article  CAS  Google Scholar 

  3. Calhoun H (2005) After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet 366: 1829–1831

    Article  Google Scholar 

  4. Rubins HR et al. (2002) Diabetes, plasma insulin, and cardiovascular disease subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162: 2597–2604

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Professor of Pharmacology, and Chief of the Section of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA

    Theodore Mazzone

Authors
  1. Theodore Mazzone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodore Mazzone.

Ethics declarations

Competing interests

Dr Mazzone is a consultant/speaker for Abbott, Pfizer and Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazzone, T. What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes?. Nat Rev Endocrinol 2, 366–367 (2006). https://doi.org/10.1038/ncpendmet0200

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0200

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing